Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
MMWR Morb Mortal Wkly Rep ; 66(38): 1023-1026, 2017 Sep 29.
Article in English | MEDLINE | ID: mdl-28957037

ABSTRACT

Approximately 75% of all hepatitis C virus (HCV) infections in the United States and 73% of HCV-associated mortality occur in persons born during 1945-1965, placing this birth cohort at increased risk for liver cancer and other HCV-related liver disease (1). In the United States, an estimated 2.7 million persons are living with HCV infection, and it is estimated that up to 75% of these persons do not know their status. Since 2012, CDC has recommended that persons born during 1945-1965 receive one-time HCV testing. To increase the number of persons tested for HCV and to ensure timely diagnosis and linkage to care, in 2014, New York enacted a hepatitis C testing law that requires health care providers to offer HCV antibody screening to all persons born during 1945-1965 who are receiving services in primary care settings or as hospital inpatients, and to refer persons with positive HCV antibody tests for follow-up health care, including an HCV diagnostic test (i.e., HCV RNA).* The New York State Department of Health (NYSDOH) used survey data from clinical laboratories and Medicaid claims and encounter data, and state and New York City (NYC) HCV surveillance data to assess the number of persons tested for HCV and number of persons with newly diagnosed HCV infections who were linked to care. During the first year of the HCV law implementation, there was a 51% increase in specimens submitted for HCV testing to surveyed clinical laboratories; testing rates among active Medicaid clients increased 52%, and linkage to care among persons with newly diagnosed HCV infection increased approximately 40% in New York and 11% in NYC. These findings highlight the potential for state laws to promote HCV testing and the utility of HCV surveillance and Medicaid claims data to monitor the quality of HCV testing and linkage to care for HCV-infected persons.


Subject(s)
Health Personnel/legislation & jurisprudence , Hepatitis C/diagnosis , Mandatory Programs , Mass Screening/legislation & jurisprudence , Aged , Hepatitis C/epidemiology , Humans , Middle Aged , New York/epidemiology , Program Evaluation
3.
Int J Drug Policy ; 18(5): 417-25, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17854731

ABSTRACT

BACKGROUND: New York State is home to an estimated 230,000 individuals chronically infected with hepatitis C virus (HCV) and roughly 171,500 active injection drug users (IDUs). HCV/HIV co-infection is common and models of service delivery that effectively meet IDUs' needs are required. A HCV strategic plan has stressed integration. METHODS: HCV prevention and care are integrated within health and human service settings, including HIV/AIDS organisations and drug treatment programmes. Other measures that support comprehensive HCV services for IDUs include reimbursement, clinical guidelines, training and HCV prevention education. Community and provider collaborations inform programme and policy development. RESULTS: IDUs access 5 million syringes annually through harm reduction/syringe exchange programmes (SEPs) and a statewide syringe access programme. Declines in HCV prevalence amongst IDUs in New York City coincided with improved syringe availability. New models of care successfully link IDUs at SEPs and in drug treatment to health care. Over 7000 Medicaid recipients with HCV/HIV co-infection had health care encounters related to their HCV in a 12-month period and 10,547 claims for HCV-related medications were paid. The success rate of transitional case management referrals to drug treatment is over 90%. Training and clinical guidelines promote provider knowledge about HCV and contribute to quality HCV care for IDUs. Chart reviews of 2570 patients with HIV in 2004 documented HCV status 97.4% of the time, overall, in various settings. New HCV surveillance systems are operational. Despite this progress, significant challenges remain. DISCUSSION: A comprehensive, public health approach, using multiple strategies across systems and mobilizing multiple sectors, can enhance IDUs access to HCV prevention and care. A holisitic approach with integrated services, including for HCV-HIV co-infected IDUs is needed. Leadership, collaboration and resources are essential.


Subject(s)
Community Health Services/organization & administration , HIV Infections/therapy , Harm Reduction , Health Knowledge, Attitudes, Practice , Health Policy , Health Services Accessibility/organization & administration , Hepatitis C/therapy , Substance Abuse, Intravenous/therapy , Community Health Services/economics , Community Pharmacy Services/organization & administration , HIV Infections/economics , HIV Infections/epidemiology , HIV Infections/prevention & control , HIV Infections/transmission , Health Policy/economics , Health Services Accessibility/economics , Hepatitis C/economics , Hepatitis C/epidemiology , Hepatitis C/prevention & control , Hepatitis C/transmission , Humans , Insurance, Health, Reimbursement , Medicaid , Medical Waste Disposal , Medically Uninsured , Models, Organizational , Needle-Exchange Programs/organization & administration , New York/epidemiology , Patient Education as Topic , Population Surveillance , Practice Guidelines as Topic , Prisoners , Program Development , Quality of Health Care , Substance Abuse, Intravenous/economics , Substance Abuse, Intravenous/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...